Calliditas February 2023 Update: The proof is in the pudding - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas February 2023 Update: The proof is in the pudding - Redeye

{newsItem.title}

Calliditas recorded Q4 Tarpeyo sales of SEK 169m which is impressive even if it is just below our and the markets expectations. The number of unique (US) subscribers has increased by 34% to 642 in Q4 (from Q3). Calliditas provides the first full year Tarpeyo sales guide for 2023 (strict US product sales) and this is a USD range of USD 120m to 150m. Our updated view is a base case valuation of SEK 315 (285) and a Bull Case of SEK 500 (500) and a Bear Case of SEK 95 (95)

Länk till analysen i sin helhet: https://www.redeye.se/research/885385/calliditas-february-2023-update-the-proof-is-in-the-pudding?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt